TMCnet News
NeuroMetrix to Exhibit at International MeetingWALTHAM, Mass. --(Business Wire)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported today that it will be an exhibitor and sponsor at the 15th Malvern Diabetic Foot Conference May 14-16, 2014 in Malvern, United Kingdom, at the Malvern Theatres. "We are pleased to be invited as an exhibiting sponsor to this premier diabetes conference," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer, NeuroMetrix. "This is an opportunity to showcase our SENSUS™ device for treating chronic neuropathic pain and our NC-stat® DPNCheck® test for detecting diabetic peripheral neuropathy to European leaders in the care of patients with diabetes. It may also provide insight into the European market opportunity for our products." The Malvern Diabetic Foot Conference is the longest-standing international diabetic foot meeting held globally every other year. The current conference will be the fiteenth meeting since its inception in 1986. The event brings together experts on the diabetic foot from up to 30 countries, predominantly North America and Western Europe. It attracts physicians, surgeons, podiatrists, orthotists and nursing staff with a common interest in diabetic foot problems with the goal of improving the understanding in this area which represents one of the main causes for in-patient treatment among the diabetic population. For more information, visit http://www.malverndiabeticfoot.org/. About NeuroMetrix NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The Company markets the SENSUS device for treating chronic pain, focusing on physicians managing patients with neuropathic pain such as painful diabetic neuropathy. The Company also markets DPNCheck, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit http://www.NeuroMetrix.com.
|
